Skip to main content
SpringerLink
Log in

Abatacept cost effective for RA with high marker levels

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. similar to the Birmingham RA model with some elements of the Sheffield RA health economic model

  2. Abatacept versus adaliMumab comParison in bioLogic-naivE

  3. 2015 British pounds

Reference

  • Alemao E, et al. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. Value in Health : 1 Jul 2017. Available from: URL: https://doi.org/10.1016/j.jval.2017.05.020

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abatacept cost effective for RA with high marker levels. PharmacoEcon Outcomes News 782, 6 (2017). https://doi.org/10.1007/s40274-017-4137-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4137-y

Search

Navigation